This is an original excerpt written by our team to show structure, depth and referencing. It is modelled on the course named above but is not a university document. Use samples as a study guide and follow your school's academic integrity policy.
Case
The patient is illustrative. Mrs. V., 72, is found to have atrial fibrillation during a routine visit. She has hypertension and type 2 diabetes, no history of stroke, heart failure or vascular disease, and no bleeding history. She weighs 68 kg, and her serum creatinine is 1.1 mg/dL. She takes lisinopril, metformin and, on her own, aspirin 81 mg "for her heart." She has no mechanical heart valve and no mitral stenosis.
Question 1: What is her stroke risk?
Using CHA₂DS₂-VASc:
| Risk factor | Points |
|---|---|
| Congestive heart failure | 0 |
| Hypertension | 1 |
| Age 75 or older | 0 |
| Diabetes | 1 |
| Prior stroke or TIA | 0 |
| Vascular disease | 0 |
| Age 65 to 74 | 1 |
| Female sex | 1 |
| Total | 4 |
The 2023 ACC/AHA/ACCP/HRS atrial fibrillation guideline recommends anticoagulation for patients with an estimated annual stroke risk of 2% or more, which corresponds to a CHA₂DS₂-VASc score of 2 or more in men and 3 or more in women (Joglar et al., 2024). With a score of 4, Mrs. V. should be offered anticoagulation.
Question 2: Which anticoagulant?
The guideline recommends direct oral anticoagulants (DOACs) over warfarin for patients with atrial fibrillation who are eligible, except those with moderate to severe mitral stenosis or a mechanical heart valve (Joglar et al., 2024). She has neither, so a DOAC is preferred. It also recommends against aspirin alone for stroke prevention in atrial fibrillation, so her aspirin should be stopped once she starts an anticoagulant, unless there is another reason for it.
Question 3: How do the DOACs work, and how should apixaban be dosed?
| Drug | Mechanism | Key pharmacokinetic points |
|---|---|---|
| Apixaban | Direct factor Xa inhibitor | Twice-daily dosing; less dependent on the kidneys than dabigatran; metabolized partly by CYP3A4 and a P-glycoprotein substrate |
| Rivaroxaban | Direct factor Xa inhibitor | Once daily with the evening meal for atrial fibrillation |
| Dabigatran | Direct thrombin inhibitor | Mostly renally cleared, so it accumulates in kidney impairment |
Apixaban's label reduces the dose to 2.5 mg twice daily only when a patient has at least two of: age 80 or older, weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher. Mrs. V. has none of these, so the correct dose is 5 mg twice daily. Underdosing is a common error that leaves patients less protected.
Question 4: What should be monitored and taught?
- Before starting: complete blood count, kidney and liver function; review interacting drugs, especially strong CYP3A4 and P-glycoprotein inhibitors or inducers.
- Ongoing: kidney function at least yearly, more often as it changes; signs of bleeding; adherence, since missed doses quickly lose protection because of the short half-life.
- Teaching: take doses about 12 hours apart; don't stop without talking to the prescriber; avoid NSAIDs and tell all clinicians, including dentists, that she takes an anticoagulant; seek care for black stools, blood in the urine, severe headache or a fall with a head injury.
Reference
Joglar, J. A., Chung, M. K., Armbruster, A. L., Benjamin, E. J., Chyou, J. Y., Cronin, E. M., Deswal, A., Eckhardt, L. L., Goldberger, Z. D., Gopinathannair, R., Gorenek, B., Hess, P. L., Hlatky, M., Hogan, G., Ibeh, C., Indik, J. H., Kido, K., Kusumoto, F., Link, M. S., . . . Van Wagoner, D. R. (2024). 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 149(1), e1–e156. https://doi.org/10.1161/CIR.0000000000001193
